Clinical Trial Title
Phase III randomized trial of standard systemic therapy (SST) versus standard systemic therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer.Contact Information
Clinical Trial Protocol Description:
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
- Have an intact prostate.
- Have received no more than 28 weeks of standard systemic therapy (SST).
This is a partial list of eligibility requirements.
Study Details
Clinical Trial Investigator
Srinivas Vourganti, MD
Contact Information
RUSH MD Anderson Cancer Center Clinical Trials Office